XASX
AVR
Market cap670mUSD
Oct 09, Last price
9.55AUD
1D
-3.44%
1Q
-28.41%
Jan 2017
-73.47%
IPO
-94.12%
Name
Anteris Technologies Ltd
Chart & performance
P/E
—
P/S
485.95
EPS
—
Div yield, %
—
Shrs. gr., 5y
21.15%
Rev. gr., 5y
-23.02%
Revenues
2m
-29.23%
Net income
-94m
L+23.40%
CFO
-78m
L+27.04%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Key people
John Seaberg
Non-Executive Independent Chairman of the Board · since 2017
Matthew McDonnell
Interim Chief Financial Officer · since 2018
David Denis
Chief Operating Officer · since 2017
Helen Wray
Vice President of Operations
Michael Oswell
Vice President - Development · since 2018
Michael Charles Bennett
Executive Director · since 2011
Danny Zanardo
Director of Sales
Lynne Bradshaw
Director of Marketing
Kiran Bhirangi
Chief Medical Officer · since 2018
Wenyi Gu
Director · since 2018
Yanheng Wu
Non-Executive Director · since 2018
Lishan Zhang
Non-Executive Director · since 2018
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||